Form 8-K - Current report:
SEC Accession No. 0001193805-23-000978
Filing Date
2023-07-12
Accepted
2023-07-12 17:27:05
Documents
13
Period of Report
2023-07-07
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 e618774_8k-plx.htm   iXBRL 8-K 29671
2 COMBINED DISCLOSURE STATEMENT AND JOINT CHAPTER 11 PLAN OF LIQUIDATION. e618774_ex99-1.pdf 8-K 1557161
  Complete submission text file 0001193805-23-000978.txt   3478502

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE plxpq-20230707.xsd EX-101.SCH 2965
4 XBRL LABEL FILE plxpq-20230707_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE plxpq-20230707_pre.xml EX-101.PRE 22362
7 EXTRACTED XBRL INSTANCE DOCUMENT e618774_8k-plx_htm.xml XML 3487
Mailing Address 9 FISHERS LANE SUITE E SPARTA NJ 07871
Business Address 9 FISHERS LANE SUITE E SPARTA NJ 07871 (713) 842-1249
PLx Pharma Winddown Corp. (Filer) CIK: 0001497504 (see all company filings)

EIN.: 271707962 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36351 | Film No.: 231085369
SIC: 2834 Pharmaceutical Preparations